About Me

Amneal to Build Two New State-of-the-Art Manufacturing Facilities in Ahmedabad

New Delhi. Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the Company”), a global pharmaceutical company based in the U.S., today announced that it will build two new state-of-the-art manufacturing facilities in Ahmedabad, expanding the Company’s longstanding presence and innovation capabilities in India.

Founded in 2002 by Chirag and Chintu Patel in New Jersey, Amneal is a global, diversified pharmaceutical company that manufactures in the U.S., India and Ireland. The Company established and has been growing its operations in India since 2008, where it has eight manufacturing sites, including five in Ahmedabad with additional sites in Dahej, Hyderabad and Vizag, and commercial offices in Mumbai. The Company has the industry’s #1 quality track record and a diverse and complex portfolio of more than 280 commercial products across Retail, Injectables, Biosimilars and Specialty – all supported by its leading global R&D and manufacturing capabilities.

In this latest expansion in India, Amneal will make a total net investment of between USD$150 million and $200 million over the next four to five years to build two new greenfield facilities – one for peptide synthesis and one for advanced sterile fill-finish manufacturing. Combined with Amneal’s existing manufacturing network, the Company will develop and supply a portfolio of next-generation branded medicines for metabolic diseases and obesity, including GLP-1 and amylin receptor agonists, in collaboration with Metsera.

“Two decades after our founding, Amneal has grown into one of the world’s most innovative and trusted pharmaceutical companies that develops, manufactures and supplies essential medicines. We have made meaningful strategic investments over the years to bolster our world-class R&D capabilities, production capacity and commercial infrastructure in India and globally. With these new facilities, we are proud to be at the forefront of developing and manufacturing innovative, branded medicines at scale in India, which will supply the local market and the rest of the world,” said Chirag and Chintu Patel, Co-Founders and Co-Chief Executive Officers.

dharmendra.bhaskar@mslgroup.com

Post a Comment

0 Comments